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Introduction
CRC represents the third most common form of cancer in humans. CRC develops frequently in the context of inflammatory bowel disease demonstrating a tumor-promoting role of inflammation. 1 Moreover, stroma immune cells support growth of CRC via production of cytokines that activate the oncogenic transcription factors NFkB and STAT3. 2 However, the stroma also contains immune cells with antitumor activities which force tumors to develop mechanisms of escape and immune suppression. 3 One paradigm is the ability of tumors to modulate polarization of TAMs. Th1 cytokines polarize macrophages toward the M1 phenotype which is responsible for innate immune attack of infectious pathogens but also neoplastic cells. Alternative activation by Th2 cytokines polarizes macrophages toward the M2 phenotype which is characterized by low expression of M1 markers (e.g., iNOS) but high expression of M2 markers (e.g., Arginase-1). 4 M2 macrophages have reduced antitumorigenic activities but promote angiogenesis and tumor progression. 4 Repolarization of M2 macrophages toward the M1 phenotype in tumors represents a promising option for antitumor therapies. 5 Another layer of complexity was recently discovered in breast tumors where an additional TAM population, distinguishably from M1 or M2 polarized macrophages, was identified. 6 STAT3 phosphorylation at tyrosine residue 705 (pY-STAT3) via Janus kinases (JAKs) is induced by pro-and anti-inflammatory cytokines such as IL-6 and IL-10. 7 The oncogenic role of STAT3 in CRC tumor cells has been demonstrated in several studies. [8] [9] [10] However, STAT3 seems to have a suppressive role in advanced CRCs because Apc Min mice lacking STAT3 in tumor cells developed aggressive intestinal carcinomas that were not observed in Apc Min control animals. [11] [12] [13] STAT3 activation in tumor cells represents an important immune escape mechanism as cancer cells exploit STAT3-induced expression of VEGF and IL-10 to blunt maturation of stroma DCs. An immune suppressive action is further given by the STAT3-dependent repression of pro-inflammatory cytokines and chemokines including IFNg, TNFa, IL-6, and CXCL10. 14, 15 Apart from tumor-cell specific functions, STAT3 is considered to promote tumor formation when being activated in stroma cells of CRCs. 13, 16, 17 Tumor transplantation experiments into mice lacking STAT3 in the hematopoietic system demonstrated that STAT3 activation in immune cells prevents antitumorigenic activities of DCs, Th1 cells, NKs, and neutrophils. 18 This led to the concept of inhibiting stroma/hematopoietic STAT3 as potential strategy for cancer immunotherapy. 19 Myeloid STAT3 is considered of particular importance for the modulation of Th1-like antitumor responses. 20 Consequently, inhibition of STAT3 in myeloid cells and B cells using CpG-STAT3 siRNA enhanced cytotoxic T cell (CTL)-mediated responses in a melanoma transplantation model. 21 Here, we demonstrate that ablation of myeloid STAT3 significantly interfered with development of autochthonous AOM/ DSS-induced colorectal tumors in mice. This effect was mediated by an enhanced antitumor T cell response. Weighted gene coexpression network analysis (WGCNA) uncovered sustained T cell-mediated immune surveillance in escaped STAT3 Dm tumors accompanied by enhanced STAT3 signaling in tumors cells which might promote immune evasion.
Results

Myeloid STAT3 promotes formation of colorectal tumors
We investigated the role of STAT3 in the myeloid stroma cells of autochthonous colorectal tumors developing under inflammatory conditions using mice with conditional inactivation of STAT3 in myeloid cells (STAT3 Dm D LysM
Cre/Cre STAT3 flox/flox ) and corresponding controls (STAT3 wt D LysM Cre/Cre STAT3 C/C ). The LysMCre knock-in alleles were kept homozygous to account for potential Cre or LysM knock-in effects. Successful deletion of STAT3 in myeloid cells was confirmed by Western blot of granulocytemacrophage precursors, FACS-sorted peritoneal macrophages (Fig. S1A) and qPCR of FACS-sorted splenic macrophages (Fig. S1B) . Histopathological analysis and IHC-staining revealed no major changes of cell differentiation or proliferation in colon and small intestine of STAT3 Dm mice (Fig. S2A) . Despite the observation that deletion of STAT3 in myeloid cells provokes Th1 differentiation and development of colitis, 22, 23 we could not detect severe colitis in STAT3 Dm mice in the C57BL/6 genetic background (Fig. S2B) . We only observed a consistently increased mean fluorescence intensity of the activating protein CD69 on CD4 C T cells in the lamina propria of DSS-treated 
STAT3
Dm mice (Fig. S3) indicative for Th1 differentiation. 24 To investigate the impact of myeloid STAT3 in autochthonous tumors, we induced CRC using AOM/DSS (Fig. 1A) . Tumor multiplicity was strongly reduced in STAT3
Dm male mice but tumor size was not affected (Fig. 1B) . Tumor analysis in female mice gave similar results (data not shown). Tumor parameters such as cell proliferation and cell survival were unaltered in STAT3
Dm CRCs (Fig. 1C ) whereas increased numbers of blood vessels were found in the tumor stroma (Fig. 1D) .
Myeloid STAT3 regulates stromalization of CRCs
Tumor progression requires the reciprocal interaction between tumor and stroma cells. Remarkably, histopathologic and immunohistochemical examination revealed an increased stromalization of STAT3 Dm CRCs ( Fig. 2A) . Histomorphometric quantitation of IHC-stained sections (Fig. S4 ) demonstrated that the relative percentages of most cell types were unaltered in the stroma of STAT3 Dm CRCs (Fig. 2B) . Interestingly, RORgt C Th17 cells were almost absent (Fig. 2B) . Among macrophages, we found a reduction of cells expressing the macrophage M2 polarization protein Arginase-1 paralleled by an increase in the number of M1 expressing iNOS-positive cells (Fig. 2C) .
Increased stromalization is frequently associated with enhanced tumor progression and invasiveness. However, no significant alteration in the percentages of low grade tumors, high grade tumors and carcinomas was observed in STAT3 Dm mice (Fig. 2D) detected ( Fig. 3A) . Similarly, numbers of NK cells in the spleen and the expression of NK cell maturation markers (CD27, KLRG-1) were unchanged ( Fig. S5A) as were the percentages of NKG2D C , NKG2A/C/E C , DNAM-1 C , and Ly49C/I C NK cells (Fig. S5B) . The only consistent changes were lower numbers of NK cells expressing the activating receptor Ly49D, which recognizes MHC-I alloantigens ( Fig. 3B) and an enhanced mean fluorescence intensity of the activating receptor NKG2D in
STAT3
Dm mice (Fig. 3C) . As NKG2D is an important receptor for the recognition of stress-induced ligands on tumors, we performed transplantation experiments with isogenic C57BL/6-derived BCR/ ABL p185 leukemia cells that are sensitive to eradication by NK cells. 26 Although BCR/ ABL p185 -derived tumors were slightly smaller in STAT3
Dm host animals, indicative for an improved NK cell-mediated tumor surveillance, the differences did not reach statistical significance (Fig. 3D) .
We next investigated the impact of NK cell-mediated immune surveillance on formation of autochthonous CRCs. For that purpose, we treated STAT5 wt and STAT5 DNK mice with AOM/DSS. STAT5
DNK mice represent a model for genetic ablation of NK cells. 27 However, no significant change in AOM/DSSinduced tumor formation was observed in STAT5 DNK mice despite of the substantial reduction of NKp46 C cell numbers in the gut (Fig. 3E) . These data suggest that NK cell-mediated killing activities do not significantly contribute to immune surveillance of AOM/DSS-induced CRCs.
Myeloid STAT3 is required for T cellmediated immune surveillance of CRCs
Apart from NK cells, CTLs and helper T cells are key determinants of tumor immune surveillance. Therefore, we performed in vivo cytotoxicity assays. m-TRP2 181-188 -immunized STAT3 Dm mice displayed a slight but significantly enhanced killing activity of m-TRP2 181-188 -pulsed CFSE-labeled splenocytes in vivo (Fig. 4A) indicating enhanced CTL activity. To address whether the enhanced T cell-dependent cytotoxicity extends to CRCs, we transplanted isogenic colorectal MC38 adenocarcinoma cells. Remarkably, MC38 tumor growth, which is controlled by T cells, 28 was significantly impaired in STAT3 Dm host animals (Fig. 4B) . Reduced tumor growth was accompanied by higher numbers of CD4 C T cells and slightly increased numbers of CD8 C cytotoxic T lymphocytes in tumor cell preparations (Fig. 4C) . The number of immature myeloid-derived suppressor cells (MDSCs) was also elevated in tumors of STAT3
Dm host mice whereas TAMs were reduced (Fig. 4C) . No changes of NK cell infiltration were observed (data not shown). Moreover, NKG2D ligand RaeI and MHC-I protein expression levels were similar on MC38 tumor cells that developed in STAT3 wt and STAT3 Dm mice (data not shown). 
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These data demonstrate enhanced T cell-mediated killing of MC38 colorectal tumors cells in STAT3 Dm host mice. We next investigated if enhanced T cell activity is also evident in the stroma of autochthonous AOM/DSS-induced STAT3
Dm
CRCs. Tumor and stroma tissue were separated by microdissection and microarray analysis was performed with isolated RNA. Genes indicative for T cell activation were upregulated in the stroma of STAT3
Dm CRCs (Fig. 4D) . In human CRCs, a gene expression profile called Immunologic Constant of Rejection (ICR) signature 29 is indicative for T cell activation and better prognosis of patients. Several genes of the human ICR signature such as stat1 were also found upregulated in murine STAT3
Dm CRCs (Fig. 4E ). STAT1 is a key factor in immune surveillance 30 and it has been shown that deletion of STAT3 shifts gp130-type cytokine signaling from a STAT3 to a STAT1 response. 31 Consistently, increased numbers of stroma cells with STAT1 protein expression and STAT1 activation were detected in STAT3 Dm CRCs (Fig. 4F) . Taken together, these data support the concept that CRC growth in STAT3 Dm mice is limited by T cell-mediated immune surveillance.
CRCs of STAT3
Dm mice escape T cell-mediated killing In order to gain further insight into immune-mediated killing and putative tumor cell-autonomous escape mechanisms of CRCs, microarray data from tumor and stroma tissues were analyzed by WGCNA. Modules of high correlation for genes implicated in immune responses and cytokine production were identified with microarray data from stroma tissue (Fig. S6) . In line with the increased density of blood vessels observed in the stroma of STAT3
Dm tumors (Fig. 1D) we also identified a module containing genes implicated in angiogenesis (Fig. S6) . This module was further stratified into positive and negative regulators of angiogenesis which revealed a bias toward increased expression of positive regulators and decreased expression of negative regulators in the stroma of STAT3
Dm tumors (Fig. S7A) . Network plots for GO terms in immune modules revealed a clear result with drastic upregulation of corresponding genes in the stroma of STAT3
Dm tumors ( Fig. 5A; Fig. S7B ). Upregulation of cytokine/chemokine receptors, MHC-II molecules and complement factors was identified in network plots ( Fig. 5A; Fig. S7B ). Implicated genes suggested a strong enhancement of immune responses related to T cell activation. In summary, these data provide strong evidence for a pronounced T cell dependent immune surveillance occurring in AOM/DSS-induced tumors in the absence of myeloid STAT3. 
Cell-autonomous changes of putative immunoediting pathways in STAT3
Dm CRCs Despite maintained T cell activation in the stroma, tumors of STAT3 Dm mice did not show a significant reduction in size (Fig. 1B) . This indicates that established CRCs in STAT3 Dm mice must have developed strategies to escape the enhanced tumor surveillance. We thus investigated the microarray expression data of the microdissected tumor cell tissue separately for processes involved in immunoediting. RNA expression of immunosuppressive tumor-derived factors (Fig. S8A) and NKG2D stress-induced ligands (Fig. S8B) were unchanged. Unaltered protein expression of the NKG2D ligand RaeI was confirmed by IHC (data not shown). As STAT3 Dm CRCs displayed increased expressing of complement factors in the stroma ( Fig. 5A ; "adaptive immune response") we investigated expression of mCRPs, which protect tumor cells from complement attack. No differences were observed (Fig. S8C) .
We next used the Molecular Signature Database of the Broad Institute to identify differentially regulated signaling pathways in tumor cells. Genes upregulated in STAT3
Dm tumor cells (>2-fold) overlapped with genes upregulated in colonic tissue after treatment with IL-22 (a potent inducer of STAT3) 32 indicating enhanced STAT3 signaling. Since STAT3 activation is a prominent mechanism involved in immune escape of tumor cells, 33 we stained STAT3 Dm tumors for STAT3 and activated nuclear pY-STAT3. Consistent with the overlap analysis, elevated levels of STAT3 and activated pY-STAT3 were evident in STAT3
Dm tumor cells (Fig. 5B) . The overlap analysis also suggested increased expression of c-Myc, a STAT3 target gene, 34 
in STAT3
Dm tumor cells which was confirmed by IHC (data not shown). In contrast, no obvious change in nuclear ß-Catenin, the major driver of CRC formation, was observed (Fig. 5B) . These data suggest that STAT3
Dm CRCs activate STAT3 signaling in tumor cells for immune escape.
Discussion
Ablation of hematopoietic STAT3 results in antitumor immune responses in murine models of tumor cell transplantation.
14 These models have certain disadvantages since tumor cell lines have been cultured for a long period of time and may not ideally reflect tumor development in vivo. Our knowledge on the role of hematopoietic STAT3 in autochthonous tumors is limited. It is also unclear if and how tumors will adapt to a different microenvironment upon deletion of STAT3 to circumvent and escape the improved immune surveillance. Thus, we deleted STAT3 in myeloid cells in a murine model of autochthonous CRCs. The use of an autochthonous model allowed us to study 
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cellular and molecular consequences of myeloid STAT3 ablation on the tumor stroma as well as on the tumor cells themselves. We found that ablation of myeloid STAT3 interfered with formation of inflammation-associated CRCs. Only few tumors evolved that seemed having adapted to escape the strong immunogenic microenvironment.
Inflammation is a strong promoter for CRC development but inflammatory infiltrates also contain immune cells with antitumor activities. 1 Loss of STAT3 in hematopoietic cells provokes inflammation in the gut albeit it remained unclear whether this condition promotes or prevents formation of colitis-associated CRCs. 23, 35, 36 Interestingly, we have not observed severe spontaneous colitis in STAT3 Dm mice. STAT3 Dm and STAT3 wt mice also responded to a comparable extent to DSS treatment regarding the activation status of intestinal inflammatory cells and ulceration score. Several reasons may underlie this discrepancy. It may be caused by the different C57BL/6 genetic background or alternatively may be related to a different intestinal microflora as STAT3
Dm associated enterocolitis reacts to ablation of TLR4 signaling. 22 The increased angiogenesis observed in STAT3
Dm CRCs remains controversial because it has been demonstrated that STAT3 activation in MDSCs and TAMs of transplanted B16 melanomas favors tumor angiogenesis. 37 However, the altered stromalization and chemokine/cytokine expression might have pleiotropic effects on angiogenesis pathways in STAT3
Dm CRCs. The observed bias toward increased expression of positive regulators and decreased expression of negative regulators in the stroma of STAT3
Dm tumors might result in a net increase of angiogenesis that cannot be attributed to a single factor. Interestingly, RORgt C Th17 cells were almost completely absent in the stroma of STAT3
Dm tumors. The role of this cell type in cancer is controversial and promoting as well as suppressive effects on angiogenesis have been reported. 38 It has been demonstrated that inflammatory cytokines from local macrophages and dendritic cells can promote a Th17-Th1 "phenotypic drift" that leads to gradual acquisition of Th1-associated gene expression by Th17 cells. This is marked by loss of Th17 cell molecules including RORgt. 39 It is possible that the STAT3-deficient myeloid cells promote a Th17-Th1 "phenotypic drift" thereby depleting the RORgt C Th17 cell population in STAT3 Dm tumors. Upon challenge with transplanted tumor cells, the MC38 studies suggest that enhanced immune surveillance in STAT3 Dm mice largely relies on myeloid cross activation of T cells. Most importantly, the stroma gene expression signatures in STAT3 Dm tumors are clearly indicative for T cell activation whereas NK cell activities seem to play a minor role. In line with this hypothesis, CRC formation was not promoted in STAT5 DNK mice which display reduced NK cell numbers and NK cell-dependent tumor surveillance 27 including a significant reduction of Nkp46 C NK cells in the gut. The presence of CD3 C , CD8 C , and CD45RO C stroma T cell infiltration and their intratumoral location in CRCs (Immunoscore) represents a better prognostic marker than conventional TNM staging. 40 The additional determination of a core gene expression signature called ICR further refines the accuracy of prognosis. 29 T cells were the most abundant stroma cell type in AOM/DSS-induced CRCs. Importantly, STAT3
Dm tumors displayed upregulation of ICR genes irf1, stat1, cxcl9, and ccl5 indicating that they represent predictive markers in mice and humans. The concept of immunoediting suggests that tumors -incompletely eradicated by the immune system -remain dormant and eventually escape immune attack (i.e. they become edited). 33 
CRCs in STAT3
Dm mice face sustained stroma T cell activities that might force them to develop additional immune evasion mechanisms. The importance of STAT3 activation in tumor cells for immune evasion is well documented 41, 42 and has been demonstrated for various cancers including glioblastoma 43, 44 and squamous cell carcinoma. 45 STAT3 is predominantly activated by IL-6 and IL-11 cytokines in CRCs. 46 This cytokine-mediated STAT3 activation is usually transient but cancer cells have developed mechanisms for persistent activation of STAT3 that depends on sphingosine signaling. 47, 48 CRCs in STAT3 Dm mice might represent a subset of survivors with particular high pY-STAT3 levels in tumor cells that selectively escaped sustained T cell activities. pY-STAT3 autoregulates its own expression 49 leading to a positive feed forward loop that might explain the high levels of total STAT3 protein in STAT3
Dm tumor cells. STAT3 inhibitors are in clinical trials for various types of cancers 50 and several immunotherapy strategies for CRC are currently tested. 51 Our data suggest that application of STAT3 inhibitors interferes with immune evasion of CRC tumor cells which would improve the efficacy of immunotherapy strategies and prevent relapse. 
Methods
Mice and in vivo experiments
F4/80
C peritoneal macrophages were FACS sorted 4 h after i.p. injection of 4% thioglycerol (Sigma). All mouse experiments were performed in accordance with Austrian and European laws and with the general regulations specified by the Good Science Practices guidelines of the Medical University of Vienna.
In vitro cytotoxicity assay of NK cells Mice were injected i.p. with PBS or 100 mg poly (I:C) to activate NK cells and spleen cells were isolated after 18 h. Splenocytes were incubated with 5 £ 10 4 CFSE-stained (2.5 mM) YAC-1 target cells at effector-to-target ratios of 100:1, 50:1 and 25:1 in triplicates in 96-well plates. To assess the extent of spontaneously occurring apoptosis, tumor cells were incubated in the absence of NK cells. After 6 h 7-AAD Viability Solution was added and cytotoxicity was quantified by flow cytometry.
Cytotoxicity was normalized to quantified NK numbers of splenic single cell suspensions.
Histology and immunohistochemistry (IHC)
Intestines were flushed with PBS and 4% buffered formaldehyde and fixed as Swiss roles in 4% formaldehyde. 4 mm paraffin sections were stained with H&E, alcian blue or IHC using standard procedures (supplemental methods).
Flow cytometric analysis
For staining of macrophages, splenic immune cells and lamina propria lymphocytes, cells were preincubated with PBS containing 0.5% BSA and FCgIII/IIR antibody to block nonspecific binding. The Cell Trace CFSE Cell Proliferation Kit (Invitrogen) and the 7-AAD Viability Solution (eBioscience) was used according to the manufacturer's instruction. Cells were stained with corresponding antibodies (supplemental methods) and analyzed using a FACSCanto TM II flow cytometer (BD Biosciences) or a FACS Fortessa (Beckton Dickinson) and data were calculated with FACSDiva software (BD Biosciences).
Microarray analysis
RNA from microdissected paraffin material was labeled and hybridized to mouse whole genome GeneChip Mouse Gene 2.0ST arrays (Affymetrix) according to manufacturer's instructions. Microarray data were analyzed using Limma package of R with the parameters "mouse," "tissue type" (tumor and stroma) and "genotype" using a paired approach with "mouse" as pairing variable.
55 p values were adjusted according to Benjamini-Hochberg. 56 An adjusted p value < 0.05 was considered as significant. Data are available at GEO via accession number GSE60871.
Weighted Gene Co-expression Network Analysis (WGCNA)
The Pearson correlations were calculated for all pairs of genes in the samples. The resulting correlation matrix was transformed into a matrix of connection strengths by raising the absolute value of the correlation coefficients to the power ß. A ß of 6 was used to satisfy the scale free topology criterion. 57 The top 25% of genes displaying the highest variability over the entire dataset were selected for module detection. From these genes, modules were determined using the "blockweise" module detection function of the WGCNA package with default values except for the minimal module size and the merge cut height parameters (set to 20 and 0.05, respectively). Biological functions of the single modules were determined using the GO term enrichment analysis function of WGCNA. Only "biological function" ontology was included into the analysis. 58 p values of enriched terms were adjusted as above according to Benjamini-Hochberg. An adjusted p value < 0.05 was considered as significant.
Statistics
Significant differences in tumor parameters, IHC stainings and RT-PCR data were calculated with GraphPad Prism 5 software using unpaired t test and Mann-Whitney test. Multiple comparisons were calculated with One-way Anova and Bonferroni post-test. Significant differences between experimental groups were: *p < 0.05, **p < 0.01, or ***p < 0.005.
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